a Guangzhou School of Clinical Medicine , Southern Medical University (Guangzhou General Hospital of Guangzhou Military Region) , Guangzhou , Guangdong , China.
b The Key Laboratory of Trauma Treatment and Tissue Repair of Tropical Area , PLA , Guangzhou , Guangdong , China.
Platelets. 2019;30(6):773-792. doi: 10.1080/09537104.2018.1514110. Epub 2018 Sep 25.
As the aged population continues to markedly increase worldwide, the incidences of diabetes mellitus (DM) and cardiovascular disease (CVD) are increasing. In this study, we investigated the effects of aging, DM, and antiplatelet drugs on growth factors and anti-aging proteins in platelet-rich plasma (PRP). The study participants were classified into the following four groups: Group A, healthy individuals aged ≤45 years; Group B, healthy individuals aged >45 years; Group C, DM patients aged >45 years; and Group D, CVD patients aged >45 years taking antiplatelet drugs. The concentrations of epidermal growth factor (EGF), fibroblast growth factor (FGF)-2, platelet-derived growth factor (PDGF)-AA, PDGF-AB/BB, vascular endothelial growth factor (VEGF)-A, tissue inhibitor of metalloproteinase 2 (TIMP2), insulin-like growth factor 1 (IGF-1), growth differentiation factor (GDF)11, and clusterin in PRP samples were determined to analyze the effects of aging, DM, and antiplatelet drugs. Overall, the concentrations of IGF-1, TIMP2, and clusterin did not vary significantly between the four groups. The concentrations of PDGF-AB/BB ( = 0.010), VEGF-A ( = 0.000), and GDF11 ( = 0.026) were significantly different between Group A and Group B. Further, the concentrations of EGF ( = 0.000) and GDF11 ( = 0.000) were significantly different between Groups B and C. The concentrations of EGF ( = 0.001), VEGF-A ( = 0.000), and GDF11 ( = 0.002) significantly differed between Groups A and C. The concentrations of FGF-2 ( = 0.048), PDGF-AA ( = 0.03), and GDF11 ( = 0.001) were significantly different between Groups B and D. The concentrations of PDGF-AB/BB ( = 0.032), VEGF-A ( = 0.010), and GDF11 ( = 0.02) significantly differed between Groups A and D. We found that PRP contains high concentrations of the growth factors, TIMP2 and GDF11. Aging, DM, and antiplatelet drugs can decrease the concentration of some growth factors and GDF11, which weakens the regenerative capacity and anti-aging effects of PRP and reduces the quality of PRP.
随着全球人口老龄化的显著增加，糖尿病（DM）和心血管疾病（CVD）的发病率也在上升。本研究旨在探讨血小板富血浆（PRP）中生长因子和抗衰老蛋白随年龄、DM 和抗血小板药物的变化。研究参与者分为以下四组：A 组，年龄≤45 岁的健康个体；B 组，年龄>45 岁的健康个体；C 组，年龄>45 岁的 DM 患者；D 组，年龄>45 岁且服用抗血小板药物的 CVD 患者。测定 PRP 样本中表皮生长因子（EGF）、成纤维细胞生长因子（FGF）-2、血小板衍生生长因子（PDGF）-AA、PDGF-AB/BB、血管内皮生长因子（VEGF）-A、金属蛋白酶组织抑制剂 2（TIMP2）、胰岛素样生长因子 1（IGF-1）、生长分化因子（GDF）-11 和聚集素的浓度，以分析年龄、DM 和抗血小板药物的影响。总体而言，IGF-1、TIMP2 和聚集素在四组间的浓度无显著差异。PDGF-AB/BB（=0.010）、VEGF-A（=0.000）和 GDF11（=0.026）的浓度在 A 组和 B 组间有显著差异。此外，EGF（=0.000）和 GDF11（=0.000）的浓度在 B 组和 C 组间有显著差异。EGF（=0.001）、VEGF-A（=0.000）和 GDF11（=0.002）的浓度在 A 组和 C 组间有显著差异。FGF-2（=0.048）、PDGF-AA（=0.03）和 GDF11（=0.001）的浓度在 B 组和 D 组间有显著差异。PDGF-AB/BB（=0.032）、VEGF-A（=0.010）和 GDF11（=0.02）的浓度在 A 组和 D 组间有显著差异。我们发现 PRP 含有高浓度的生长因子、TIMP2 和 GDF11。年龄、DM 和抗血小板药物可降低某些生长因子和 GDF11 的浓度，削弱 PRP 的再生能力和抗衰老作用，降低 PRP 的质量。
Zotero 插件